CCR5[DELTA]32 Genotype Leads to a Th2 Type Directed Immune Response in ESRD Patients

In patients with end stage renal disease (ESRD) we observed protection from inflammation-associated mortality in CCR5[DELTA]32 carriers, leading to CCR5 deficiency, suggesting impact of CCR5[DELTA]32 on inflammatory processes. Animal studies have shown that CCR5 deficiency is associated with a more pronounced Th2 type immune response, suggesting that in human CCR5[DELTA]32 carriers the immune response may be more Th2 type directed. So, in the present study we determined the Th1-Th2 type directed immune response in ESRD patients carrying and not carrying the CCR5[DELTA]32 genetic variant after stimulation. We tested this hypothesis by determining the levels of IFN-[gamma] and IL-4 and the distribution of Th1, Th2 and Th17 directed circulating CD4+ and CD8+ T cells and regulatory T cells (Tregs) after stimulation in ESRD patients with (n = 10) and without (n = 9) the CCR5[DELTA]32 genotype. The extracellular levels of IFN-[gamma] and IL-4 did not differ between CCR5[DELTA]32 carriers and non carriers. However, based on their intracellular cytokine profile the percentages IL-4 secreting CD4+ and CD8+ T cells carrying the CCR5[DELTA]32 genotype were significantly increased (p = 0.02, respectively p = 0.02) compared to non carriers, indicating a more Th2 type directed response. Based on their intracellular cytokine profile the percentages IFN-[gamma] and IL-17 secreting T cells did not differ between carriers and non-carriers nor did the percentage Tregs, indicating that the Th1, Th17 and T regulatory response was not affected by the CCR5[DELTA]32 genotype. This first, functional human study shows a more pronounced Th2 type immune response in CCR5[DELTA]32 carriers compared to non carriers. These differences may be involved in the previously observed protection from inflammation-associated mortality in ESRD patients carrying CCR5[DELTA]32.